Drug Index


Mechanism :

Raxibacumab is a recombinant human IgG1 lambda monoclonal antibody which binds and neutralizes free protective antigen (PA) component of Bacillus anthracis toxin.

Indication :

  • Treatment of inhalational anthrax following exposure to Bacillus anthracis in combination with appropriate antimicrobial therapy

Contraindications :

No contraindications.

Dosing :

≤15 kg:
80 mg/kg as a single dose.
>15 kg to 50 kg:
60 mg/kg as a single dose.
>50 kg:
40 mg/kg as a single dose.
Note: Administer diphenhydramine ≤1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions.

Adverse Effect :

Skin rash, pain, pruritus.

Interaction :

Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.

Hepatic Dose :

No dosage adjustments are recommended; effects not studied.
03/24/2024 11:20:57 Raxibacumab
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0